Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure

This is a summary. Read the complete story at Yahoo Finance below.

Related Stories

marketsabout 5 hours ago

AT&T’s stock looks like the smartest bet in the wireless sector, analyst says

An analyst at BNP has taken a positive view of AT&T’s stock, writing that investors should have “little to quibble with on the mobile side.”

MarketWatch

marketsabout 6 hours ago

Bitcoin hits an 8-month high — and sends a clear message about risk appetite right now

The lack of clarity around crypto’s regulatory framework hasn’t stopped bitcoin from surging, as investors haven’t abandoned hopes for clearer U.S. rules.

MarketWatch

marketsabout 6 hours ago

As the S&P 500 nears a new record high, there are signs of weakness below the surface

About 60% of the stocks in the S&P 500 are down more than 20% from their all-time highs.

MarketWatch